Join the Ulcerative Colitis - Maintenance group to help and get support from people like you.
Ulcerative Colitis - Maintenance News
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 – There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD)...
Study IDs Risk Factors for Extraintestinal Manifestations of IBD
WEDNESDAY, April 17, 2024 – Certain demographic, clinical, and genetic factors heighten the risk for extraintestinal manifestations (EIMs) with inflammatory bowel disease (IBD), according to a study...
Higher Use of Any Rx Medications Seen Years Before IBD Diagnosis
FRIDAY, Jan. 19, 2024 – Individuals with inflammatory bowel disease (IBD) universally show increased prescription medication use years before diagnosis, according to a study published in the...
Persistent Fluorinated Chemicals Tied to Higher Risk for Inflammatory Bowel Disease
FRIDAY, Jan. 12, 2024 – Perfluoroalkyl and polyfluoroalkyl substance (PFAS) exposure is associated with later occurrence of inflammatory bowel disease (IBD), according to a research letter published...
Inflammatory Bowel Disease Phenotypes Vary by Race, Birthplace
MONDAY, Jan. 8, 2024 – For patients with inflammatory bowel disease (IBD), phenotype varies by race, and foreign-born patients of all races have later onset and milder disease, according to a study...
Crohn's, Colitis Vary by Race, Gender
FRIDAY, Jan. 5, 2023 – Crohn's disease and ulcerative colitis show different patterns of incidence by race, gender and even place of birth, a new U.S. study finds. The two illnesses are each...
ACG: Intestinal Ultrasound Monitoring Cuts Time to Treatment Change in IBD
WEDNESDAY, Oct. 25, 2023 – For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a...
FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
TUESDAY, Oct. 17, 2023 – The U.S. Food and Drug Administration approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC). The approval was based on results...
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 – Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open. Osama Hamid, M.B.B.S., from the Cleveland...
U.S. FDA Approves Subcutaneous Administration of Takeda's Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 27, 2023 – Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of Entyvio® (v...
5-ASA Discontinuation Common Within First Year of Ulcerative Colitis Diagnosis in Youth
WEDNESDAY, Sept. 20, 2023 – For adolescents and young adults diagnosed with ulcerative colitis (UC), the rate of discontinuation of 5-aminosalicylic acid (5-ASA) maintenance treatment is high within...
Higher Belly Fat Percentage Tied to Worse Outcomes for IBD Patients
WEDNESDAY, Aug. 2, 2023 – For patients with inflammatory bowel disease (IBD), higher intra-abdominal visceral adipose tissue (IA-VAT) as a percentage of total body mass is associated with worse...
Belly Fat Can Hamper Effectiveness of Meds for Crohn's, Colitis
MONDAY, July 31, 2023 – Some medications may not treat inflammatory bowel disease (IBD) as effectively if patients carry a lot of excess belly fat, , new research shows. IBD includes illnesses such...
New Drug Awaiting FDA Approval, Omvoh, Could Boost Outcomes for People With Ulcerative Colitis
TUESDAY, July 18, 2023 – People living with the pain, bloody diarrhea and sometimes urgent need to use the toilet that comes with ulcerative colitis may soon have a new treatment option that’s a...
Mirikizumab Tops Placebo for Moderately-to-Severely Active Ulcerative Colitis
FRIDAY, July 7, 2023 – For patients with moderately-to-severely active ulcerative colitis, mirikizumab is more effective than placebo for inducing and maintaining clinical remission, according to a...
Ask a question
To post your own question to this support group, sign in or create an account.